Grindeks, continues to strengthen its global presence by entering new export markets. This year, for the first time, Grindeks products will be delivered to Panama. The company's export markets already include countries such as Chile, Mexico, Australia, Singapore, the Philippines, and most of Europe. Active pharmaceutical ingredients are also exported to Japan, South Korea, and the USA.

Grindeks is a prequalified supplier for the World Health Organization, supplying its manufactured injections to international organizations such as UNFPA and UNICEF. These organizations distribute the products to African countries like Kenya, Tanzania, Liberia, Sudan, Burkina Faso, Zimbabwe, and others.

Kirovs Lipmans, Chairman of the Council of Grindeks, highlights: "Expanding into new export markets is a testament to our long-term vision and dedication to global healthcare. By continuously investing in innovation, quality, and regulatory excellence, we ensure that Grindeks remains a trusted name worldwide. Our presence in diverse markets reflects our commitment to providing effective and accessible medicines to those who need them most."

Ph.D. Juris Juris Hmelnickis, CEO of Grindeks, emphasizes: "Export for us means more than just business -- it is an opportunity to make a significant contribution to global health. Each of our export markets symbolizes not just expansion but also our commitment to improving health and quality of life worldwide. We are proud to deliver our products across regions including Europe, Asia, Latin America, and Africa, where the need for high-quality and affordable medicines is critically important. The path to global markets is not easy—it requires adapting to diverse regulations, market requirements, and cultural differences. These challenges motivate us to become even stronger, more efficient, and innovative, ensuring that Grindeks quality and reliability are accessible wherever they are needed."